Ophthalmic Drugs Market Summary

The global ophthalmic drugs market size was estimated at USD 38.20 billion in 2024 and is projected to reach USD 62.08 billion by 2030, growing at a CAGR of 8.5% from 2025 to 2030. This growth is largely driven by the rising prevalence of eye diseases, improvements in drug delivery technologies, and an increasing emphasis on research aimed at developing innovative therapeutics. As the burden of conditions such as glaucoma, macular degeneration, and diabetic retinopathy continues to rise, ophthalmic drugs play an increasingly vital role in preserving vision and enhancing quality of life for patients worldwide.

Moreover, increasing investment by public and private organizations is further propelling market expansion. These investments support clinical research, product development, and advanced treatment approaches. For instance, in July 2023, the National Eye Institute announced funding of USD 2.5 million spread over 5 years to support research on improving glaucoma treatments at Missouri University of Science and Technology. Such initiatives highlight the growing global commitment to addressing complex eye disorders through scientific innovation.

Key Market Trends & Insights

• North America dominated the global ophthalmic drugs market and accounted for a 42.7% share in 2024, supported by advanced healthcare infrastructure, high awareness levels, and strong adoption of novel therapeutics.
• The ophthalmic drugs market in the U.S. is expected to witness significant growth over the forecast period, driven by rising patient populations, expanding research programs, and a steady introduction of new treatment options.
• By disease, retinal disorders led the market in 2024 and are anticipated to grow at the fastest rate over the forecast period, reflecting increasing diagnoses and the need for effective long-term management.
• By route of administration, the topical segment led the market in 2024, as topical formulations are widely preferred for their convenience, noninvasive nature, and rapid absorption.
• By dosage form, eye drops led the market in 2024 and are anticipated to grow at the fastest rate during the forecast period, supported by their ease of use, broad applicability, and widespread availability.

Order a free sample PDF of the Ophthalmic Drugs Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 38.20 Billion
• 2030 Projected Market Size: USD 62.08 Billion
• CAGR (2025-2030): 8.5%
• North America: Largest market in 2024

Key Companies & Market Share Insights

Some of the key players operating in the market include Alcon; Novartis AG; Bausch Health Companies, Inc.; Merck & Co., Inc.and others. The market is highly competitive, with a large number of manufacturers accounting for a majority of the share. New source developments, mergers and acquisitions, and collaborations are major strategies these players adopt to counter the high competition.

Key Players

• Alcon
• Novartis AG
• Bausch Health Companies, Inc.
• Merck & Co., Inc.
• Regeneron Pharmaceuticals, Inc.
• Coherus BioSciences, Inc.
• AbbVie, Inc. (Allergan)
• Pfizer, Inc.
• Bayer AG
• Santen Pharmaceutical Co., Ltd.
• Roche (Genentech, Inc.)
• Nicox

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

In conclusion, the global ophthalmic drugs market is set for strong and consistent expansion as the prevalence of eye disorders continues to rise and innovation in treatment modalities accelerates. Advancements in drug delivery, growing research investments, and increasing availability of targeted therapies are enhancing patient outcomes and driving market demand. North America remains a key contributor, while emerging developments in retinal disorder treatments and topical formulations further strengthen industry growth. As healthcare systems place greater emphasis on early diagnosis and effective management of vision-threatening conditions, the ophthalmic drugs market is expected to maintain its upward trajectory through 2030.